Autolus Therapeutics looks undervalued as revenue grows and autoimmune catalysts near. Read here for a detailed analysis of AUTL stock.
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.
On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product revenue hit $45.7 million, up 119% from $20.9 million a year earlier and up from $26.2 million just one quarter prior. Management used the momentum to raise full-year 2026 guidance […]
Detailed price information for Stryker Corp (SYK-N) from The Globe and Mail including charting and trades.
Autolus Therapeutics (AUTL) said Wednesday that the US Food and Drug Administration has granted rege
Tipranks Press Release.
Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.